Novel CRISPR-Cas9 approach achieves durable remission in treatment-resistant B-cell lymphoma
Chen L, Patel R, Vasquez M, et al. • Nature Medicine • PMID SEED001
✨ AI-Generated Summary
Researchers used CRISPR gene editing to modify patient immune cells, achieving long-term remission in patients who had failed standard chemotherapy. Nine of eighteen patients remained cancer-free at two years.
⚠ AI summaries are generated automatically and may contain errors. Always refer to the
original abstract and full article for clinical or research decisions.
Abstract
A phase I clinical trial evaluated a next-generation CRISPR-Cas9 gene-editing strategy targeting CD19 in patients with relapsed or refractory B-cell lymphoma. Fourteen of eighteen enrolled patients achieved complete remission at six months, with nine maintaining remission at two years.